作为“最大购买方”，医保如何托举医药创新？山东这么办

Core Viewpoint - The healthcare department plays a crucial role as the largest purchaser of pharmaceutical products, facilitating high-quality development in the pharmaceutical industry through various measures [1] Group 1: Optimization of Product Listing - Shandong has established a green channel for product listing since 2021, allowing for expedited approval of innovative products, with the review frequency reduced from once a month to once a week [2] - A total of 420 pharmaceutical products from Shandong enterprises have been listed through the green channel since the start of the 14th Five-Year Plan [2] - The provincial healthcare bureau will continue to optimize the green listing mechanism, allowing for real-time acceptance and time-limited processing of applications for innovative drugs and medical consumables [2] Group 2: Payment Mechanism Improvement - During the 14th Five-Year Plan, 49 new drugs from Shandong were added to the national medical insurance drug list, which is vital for the commercialization of innovative drugs [3] - The provincial healthcare bureau aims to increase the number of Shandong innovative drugs included in the national medical insurance list through negotiations [3] - Innovative drugs will be compensated separately through special agreements, and patients can enjoy the same reimbursement benefits when purchasing drugs from designated retail pharmacies as they would in designated medical institutions [3] Group 3: Multi-layered Security System - The provincial healthcare bureau has guided all 16 cities to launch customized commercial health insurance, effectively supplementing basic medical insurance for high medical costs and expenses outside the insurance directory [4] - A guideline list for customized commercial health insurance has been established, including around 40 special drugs for cancer treatment and over 10 rare disease drugs, providing broader payment options for innovative drugs [4] - The provincial healthcare bureau will enhance collaboration with relevant departments to continuously optimize the guideline list and include more innovative drugs in the compensation scope [4]